Polyrizon Ltd. Ordinary Shares (PLRZ) is a publicly traded Healthcare sector company. As of May 21, 2026, PLRZ trades at $13.57 with a market cap of $25.66M and a P/E ratio of 0.00. PLRZ moved +1.57% today. Year to date, PLRZ is +7.11%; over the trailing twelve months it is +73.72%. Its 52-week range spans $2.88 to $7,200.00. Rallies surfaces PLRZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in PLRZ news today?
Polyrizon Unveils Preclinical Intranasal Hydrogel Blocking Respiratory Viruses: Polyrizon’s preclinical Capture&Contain™ intranasal hydrogel has shown in vitro blockade of multiple respiratory viruses, including influenza and coronaviruses, preserving cell viability in dynamic exposure models. The non-specific barrier technology addresses emerging Hantavirus clusters and aims for immediate deployability prior to strain-specific vaccines.
PLRZ analyst coverage data. Average price target: $0.00.
Common questions about PLRZ
What changed in PLRZ news today?
Polyrizon Unveils Preclinical Intranasal Hydrogel Blocking Respiratory Viruses: Polyrizon’s preclinical Capture&Contain™ intranasal hydrogel has shown in vitro blockade of multiple respiratory viruses, including influenza and coronaviruses, preserving cell viability in dynamic exposure models. The non-specific barrier technology addresses emerging Hantavirus clusters and aims for immediate deployability prior to strain-specific vaccines.
Does Rallies summarize PLRZ news?
Yes. Rallies summarizes PLRZ news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is PLRZ research on Rallies investment advice?
No. Rallies provides research, data, and educational context for PLRZ. It does not provide personalized investment advice.
